LLY

999.72

-0.87%↓

JNJ

228.72

-0.55%↓

ABBV

209.65

-0.64%↓

UNH

392.43

-1.41%↓

AZN

181.63

-2.12%↓

LLY

999.72

-0.87%↓

JNJ

228.72

-0.55%↓

ABBV

209.65

-0.64%↓

UNH

392.43

-1.41%↓

AZN

181.63

-2.12%↓

LLY

999.72

-0.87%↓

JNJ

228.72

-0.55%↓

ABBV

209.65

-0.64%↓

UNH

392.43

-1.41%↓

AZN

181.63

-2.12%↓

LLY

999.72

-0.87%↓

JNJ

228.72

-0.55%↓

ABBV

209.65

-0.64%↓

UNH

392.43

-1.41%↓

AZN

181.63

-2.12%↓

LLY

999.72

-0.87%↓

JNJ

228.72

-0.55%↓

ABBV

209.65

-0.64%↓

UNH

392.43

-1.41%↓

AZN

181.63

-2.12%↓

Kodu・Aktsiate loetelu・Emergent BioSolutions Inc

Emergent BioSolutions Inc

Avatud

SektorTervishoid

7.95 -3.52

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.93

Max

8.27

Põhinäitajad
By Trading Economics
Sissetulek	61M 6.8M
Müük	7.4M 156M
P/E Sektori keskmine	8.634 51.415
Aktsiakasum	0.21
Kasumimarginaal	4.356
Töötajad	900
EBITDA	28M 35M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+44.06% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	47M 462M
Eelmine avamishind	11.47
Eelmine sulgemishind	7.95

Uudiste sentiment

By Acuity

100%

332 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

4.95 / N/A Toetus ja vastupanu

Emergent BioSolutions Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. mai 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14. mai 2026, 22:27 UTC

Omandamised, ülevõtmised, äriostud

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14. mai 2026, 22:12 UTC

Tulu

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14. mai 2026, 21:52 UTC

Omandamised, ülevõtmised, äriostud

LVMH to Sell Marc Jacobs

15. mai 2026, 00:00 UTC

Tulu

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14. mai 2026, 23:57 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14. mai 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14. mai 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14. mai 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14. mai 2026, 23:47 UTC

Tulu

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14. mai 2026, 23:47 UTC

Tulu

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14. mai 2026, 23:46 UTC

Tulu

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14. mai 2026, 23:46 UTC

Tulu

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14. mai 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14. mai 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. mai 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14. mai 2026, 22:11 UTC

Omandamised, ülevõtmised, äriostud

LVMH Agrees to Sell Marc Jacobs -- WSJ

14. mai 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14. mai 2026, 22:00 UTC

Tulu

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14. mai 2026, 21:55 UTC

Tulu

Nu Holdings 1Q EPS 18c >NU

14. mai 2026, 21:55 UTC

Tulu

Nu Holdings 1Q Rev $4.97B >NU

Võrdlus sarnastega

Hinnamuutus

Emergent BioSolutions Inc Prognoos

Hinnasiht

By TipRanks

44.06% tõus

12 kuu keskmine prognoos

Keskmine 12 USD 44.06%

Kõrge 12 USD

Madal 12 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Emergent BioSolutions Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Emergent BioSolutions Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

4.95 / N/AToetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

332 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.